Lack of effect of oral contraceptive use on the pharmacokinetics of quinine.
The pharmacokinetics of quinine after a single 600 mg oral dose of quinine sulphate were studied in seven female subjects who used oral contraceptives and in seven age-matched female controls who did not. There were no significant differences (P greater than 0.05) in the maximum plasma concentration (Cmax) and the time of peak concentration (tmax) between the subjects who used oral contraceptives (Cmax = 5.3 +/- 1.0 (s.d.) mg l-1; tmax = 1.4 +/- 0.7 h) and the control subjects (Cmax = 5.6 +/- 0.9 mg l-1; tmax = 2.1 +/- 0.9 h). The mean elimination half-life of quinine in the oral contraceptives user group (12.5 +/- 1.9 h) was similar (P greater than 0.05) to that in the control group (11.8 +/- 2.7 h). The oral clearance of quinine in the oral contraceptive user group was 0.133 +/- 0.055 l h-1 kg-1 (range 0.073-0.233) and was not significantly different (P greater than 0.05) from that observed in the control group (0.125 +/- 0.025 l h-1 kg-1, range 0.075-0.148).
Wanwimolruk
S
S
Department of Pharmacy, University of Otago Medical School, Dunedin, New Zealand.
Kaewvichit
S
S
Tanthayaphinant
O
O
Suwannarach
C
C
Oranratnachai
A
A
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D011803:Quinine / Q000493:pharmacokinetics*
D003278:Contraceptives, Oral, Hormonal; D011803:Quinine